Invoking MCP tool get_variant_evidence with input {"diseaseName":"Melanoma","therapyName":"Dasatinib","significance":"RESISTANCE"}
MCP tool get_variant_evidence returned meta=None content=[TextContent(type='text', text='{
  "Field Descriptions": "evidenceType: Category describing the type of clinical or biological evidence (e.g., predictive, diagnostic).\
evidenceDirection: Indicates whether the evidence supports or refutes the association.\
significance: The clinical relevance of the evidence.\
description: Detailed summary of the evidence from CIViC curators.\
evidenceLevel: Describes the robustness of the study type. A - Validated association, B - Clinical evidence, C - Case study, D - Preclinical evidence, and E - Inferential association\
evidenceRating: Quality score assigned to the evidence by curators (scored 1-5).\
url: Direct link to the CIViC record for this evidence item.\
When returning information to users you MUST cite URLs used for specific information.",
  "API Results": [
    {
      "status": "SUBMITTED",
      "evidenceType": "PREDICTIVE",
      "evidenceDirection": "SUPPORTS",
      "significance": "RESISTANCE",
      "molecularProfile": {
        "variants": [
          {
            "name": "Exon 11 Mutation",
            "feature": {
              "name": "KIT"
            }
          }
        ]
      },
      "disease": {
        "displayName": "Melanoma"
      },
      "therapies": [
        {
          "name": "Dasatinib"
        }
      ],
      "variantOrigin": "SOMATIC",
      "description": "In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients, a patient harboring a KIT exon 11 Deletion mutation was reported to have no response to dasatinib monotherapy.",
      "evidenceLevel": "C",
      "evidenceRating": null,
      "url": "https://identifiers.org/civic.eid:4686"
    },
    {
      "status": "SUBMITTED",
      "evidenceType": "PREDICTIVE",
      "evidenceDirection": "SUPPORTS",
      "significance": "RESISTANCE",
      "molecularProfile": {
        "variants": [
          {
            "name": "V600E",
            "feature": {
              "name": "BRAF"
            }
          }
        ]
      },
      "disease": {
        "displayName": "Melanoma"
      },
      "therapies": [
        {
          "name": "Dasatinib"
        }
      ],
      "variantOrigin": "SOMATIC",
      "description": "In an in vitro study, a melanoma cell line, A375, expressing the BRAF V600E mutation was associated with resistance to dasatinib treatment, comparable to melanoma MEWO cells expressing wild-type BRAF. Resistance was determined by assessing cell viability.",
      "evidenceLevel": "D",
      "evidenceRating": null,
      "url": "https://identifiers.org/civic.eid:3759"
    }
  ]
}', annotations=None, meta=None)] structuredContent=None isError=False
### LLM OUTPUT ###
KIT,BRAF
